New blood test for Coronary heart disease approved by the FDA

A new blood test that could help predict coronary heart disease has been cleared by the U.S. Food and Drug Administration.

The PLAC Test monitors levels of Lp-PLA2, an enzyme in the blood that is produced inside built-up plaque by inflammatory cells in the arteries. Lp-PLA2 is a biological marker of inflammation in the arteries, which is associated with the buildup of plaque in the arteries.

Test results show that patients with Lp-PLA2 activity levels greater than 225 nanomoles per minute per milliliter (nmol/min/mL) are at greater risk of developing heart attacks or ischemic strokes associated with atherosclerosis.

The blood test could provide healthcare professionals with additional information about a patient’s health conditions along with regular cholesterol tests, which tell very little about the acute risk of heart attack or stroke.

One thought on “New blood test for Coronary heart disease approved by the FDA

  1. A continuous data type measurement as qualification and only "Increased risk" as a diagnosis?
    Not a very ground breaking "new" test in my opinion.

Leave a Reply

Your email address will not be published. Required fields are marked *